Docosahexaenoic acid metabolic pathway (DHA metabolic pathway)

The docosahexaenoic acid metabolic pathway encompasses the biosynthesis, transport, incorporation, modification, and degradation of docosahexaenoic acid (DHA), a 22-carbon, six double-bond omega-3 fatty acid essential for human health. DHA is synthesized from alpha-linolenic acid via desaturation and chain elongation steps, primarily in the liver, and can also be obtained directly from diet (especially marine sources). It is highly enriched in the brain, retina, heart, and sperm, where it is mainly incorporated into membrane phospholipids and modulates membrane fluidity and cell signaling. DHA and its metabolic products serve critical biological functions: supporting neuronal growth and survival, modulating inflammation through specialized pro-resolving mediators (e.g., protectins, resolvins), serving as ligands for nuclear receptors (e.g., PPARα), and modulating membrane protein functionality including ion channels. Altered DHA metabolism has been implicated in numerous diseases including neurodegenerative diseases, cardiovascular disease, certain cancers, metabolic syndrome, and chronic inflammatory disorders. The metabolic pathway includes several key enzymes (desaturases, elongases, cytochrome P450s, COX, LOX) and requires transport and esterification mechanisms for tissue targeting (e.g., via lysophosphatidylcholine-DHA for brain uptake)[2][3][4][5][6][7].

Other names

DHA metabolismDHA biosynthesisDocosahexaenoic acid pathwayOmega-3 fatty acid metabolismn−3 PUFA metabolic pathway

For drugs/supplements: serve as precursors to DHA, increase tissue DHA levels, alter membrane lipid composition, compete with arachidonic acid for enzymatic conversion (modulating inflammatory lipid mediator production); for pathway inhibitors—not well defined in clinical therapy.